<br>

<style justify></style> Psoriasis is a chronic, autoimmune disease of the skin and joints (Langley et al., 2005). Robert Willan, the father of modern dermatology, is credited with the first detailed clinical description of psoriasis, and hence, it is also termed as Willan'slepra (Dogra & Mahajan, 2016). Although there are five main types of of psoriasis, plaque psoriasis is the most common type, accounting for 90% of all cases (Mak et al., 2010).

Plaque psoriasis is predominantly characterized by abnormal red, silver and scaly skin patches covering the body (Dogra & Mahajan, 2016). While the pathogenesis is unclear, plaque psoriasis is attributed to a T-cell mediated hyper proliferation of keratinocyte (Gudjonsson et al., 2004). The skin patches typically appear on the scalp, back, trunk, elbows, knees, and genital areas but can also affect any other areas of the body. Distribution and severity of plaques on the body is random, and vary greatly from patient to patient from large coverage of the body in lesions to localized plaques no larger than a dime. The stigmatizing visible markings of this condition can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affected patients (Langley et al., 2005).

 Figure: Plaque psoriasis

Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805 </style>

Psoriasis is found worldwide but the prevalence varies among different ethnic groups (Dogra & Mahajan, 2016). While men and women are afflicted with equal frequency, plaque psoriasis is more common in adults then children. It also has a strong genetic predisposition but environmental factors such as infections can play an important role in the presentation of disease (Langley et al., 2005).

Currently, there is no cure for psoriasis and treatment is largely symptomatic and vary according to the severity of the disease. Earlier treatments have included application of emollients or keratolytic agents to hydrate the skin or shed off the skin (Raut et al., 2013). Later treatments, such as topical agents have been modified to treat the underlying T-cell proliferation. Systemic treatments including methotrexate, cyclosporine, acitretin, as well as light therapy are prominent for severe psoriasis(Raut et al., 2013). A combination of these therapies have provided effective and rapid modalities to suppress the disease and reduce the toxic side effects of treatment.

<br>

<style justify></style> The worldwide prevalence of psoriasis is estimated to be approximately 2–3% (Dogra & Mahajan, 2016). The disease is known to have higher prevalence in the polar regions of the world attributed to differences in sunlight exposure (Dogra & Mahajan, 2016). While psoriasis is found worldwide, the prevalence varies among different ethnic groups. It appears to be low in certain ethnic groups such as the Japanese, and may be absent in aboriginal Australians and Indians from South America (Langley et al., 2005). It is also reported to occur with similar frequency in both males and females. While psoriasis can onset at any age, the disease is less common in children than adults. The prevalence of psoriasis in adults ranged from 0.91 to 8.5 percent, and the prevalence of the disease in children ranged from 0 to 2.1 percent (Parisi et al., 2013). Plaque psoriasis appears to have a biomedical age of onset, occurring either between the ages of 15 and 20 years and or the ages of 50 and 69 years (Parisi et al., 2013).

<br>

<style float-left>

 Figure: A typical psoriatic plaque

Image from: http://www.wikipedia.com

 Figure: A red and scaly scalp lesion

Image from: http://nopsoriasis.net </style>

<style justify> Common Symptoms

Plaque psoriasis is characterized by a few main symptoms. First and foremost are the plaques, or skin lesions, themselves. These lesions are often red or silvery in colour, inflamed, scaly or dry, and generally sore or itchy (WebMD, 2017). Plaques are hyperproliferated skin cells on the epidermal layer, and is attributed to premature maturation of keratinocytes and dermal inflammatory cells. These comprise of dendritic cells, macrophages and T cells (Palfreeman et al., 2013). These skin cells with reproduce very quickly, and build up, eventually shedding in scales and patches. These patches are the most visible and obvious symptom of psoriasis, regardless of the type. Psoriasis sufferers are also afflicted by skin soreness, itchiness, and can even report a sensation of burning in the affected areas. For plaque psoriasis sufferers, approximately 50% may also experience scalp plaques (Healthline, 2017). These are similar in look to the bodily plaques. 

The location of plaques will change as the affected lesions begin to heal (Healthline, 2017). Newer patches may appear in different locations during future bouts. The symptoms of plaque psoriasis affect every sufferer differently, and no two people will experience exactly the same symptoms and plaque physiology.

The ‘Plaque’ in Plaque Psoriasis

The characteristic skin lesions of psoriasis take the form of raised plaques with silvery scales that can present on any part of the skin. The lesions usually begin as erythematous papules, and then tend to extend peripherally, eventually coalescing to form plaques (Raychaudhuri et al., 2014). However, in plaque psoriasis, the most common areas of the body that are afflicted are the scalp, back, and the extensor surfaces like knees and elbows (Palfreeman et al., 2013). Distribution of plaques on the body is generally random, and it varies greatly from patient to patient. Some may experience large coverage of the body in lesions, some may experiences plaques no larger than a dime.

New lesions can form at random, but also occur when the skin receives direct cutaneous trauma, and this is known as the Koebner phenomenon. Plaque psoriasis sufferers also experience the Auspitz phenomenon, where pinpoint bleeding occurs following a mild disruption of the superficial layer of the lesion. Plaque psoriasis is a chronic disorder, and reappearance of lesions do not necessarily occur in the same spots every time. Also, unlike inverse psoriasis, plaque psoriasis also does not afflict the genitals or armpits. </style>

<br>

<style float-right>

 Figure: Ranking the severity of psoriasis, via PASI

Image from: http://www.healthline.com </style>

<style justify> Currently, there is no set diagnostic criteria for psoriasis, and so diagnosis is made clinically through pattern recognition and a detailed morphologic evaluation of skin lesions. Based on the morphology of the lesions and locations of plaques, psoriasis has been classified into various clinical phenotypes (Raychaudhuri et al., 2014).

In this way, the simplest and most accurate way to get an accurate diagnosis of psoriasis is simply to go to the dermatologist and have the doctor assess the lesions on the affected skin. More often than not, dermatologists are very well versed in the symptomatic characteristics of psoriasis and can quickly give a visual diagnosis without the need for blood sampling or extensive testing (WebMD, 2017).

A frequent issue with visual diagnosis of psoriasis is that physiologically, this condition is very similar in look to the presentation of eczema. Patches of plaque psoriasis and eczema share the characteristics of redness, scaliness, and inflammation, making them hard to distinguish from one another (WebMD, 2017). However, psoriasis is usually also accompanied by silvery scaling as well as red. This is because psoriasis is a chronic autoimmune condition that results in the overproduction of skin cells and these dead cells build up into silvery-white scales. Eczema is typically not covered in this dead skin, as it inflammation, and not an immune compromised skin disorder. This is one key feature that can distinguish the two. Yet, sometimes psoriasis does not produce this silvery covering and can still be hard to distinguish from eczema.

When cases like this are more difficult, a skin biopsy can also be used to give a more accurate diagnosis (WebMD, 2017). In a skin biopsy, a small sample of affected skin is taken from a patient and observed under the microscope. The dermatologist will look for clubbed epidermal projections or epidermal thickening as characteristics of psoriasis lesions (Raychaudhuri et al., 2014). This technique can be used when a diagnosis is more difficult, like in the comparison to eczema, or in atypical cases (Healthline, 2017).

The clinical phenotypes of psoriasis have been classified based on factors such as age of onset, degree of skin involvement, morphologic pattern and predominant involvement of specific anatomic location of the body (Raychaudhuri et al., 2014).

Dermatologists can also rank the severity of the condition based on the Psoriasis Area and Severity Index, or PASI. This scale allows the doctor to rank the severity of the condition based on how much surface area of the skin is covered in lesions (Healthline, 2017). Less than 3% boyd coverage of plaques is considered ‘mild’, 3-10% is ‘moderate’, and anything over 10% is considered ‘severe’. This is largely at the discretion of the physician. The assessment is made by assigning an ascending score to plaque severity in terms of thickness, redness, and scaling, and the extent of the plaque spread (Healthline, 2017). </style>

<br>

<style justify>The etiology of this disease is unclear, as there is no definite cause. This is considered to be a multifactorial disease, which means that it is caused by a combination of genetic and environmental factors.  

The idea of psoriasis having a genetic basis has been accepted in the medical community for many years now. However, not all the genes that are associated with this disease have yet been identified, through the general region of these genes is known (Lowes, Bowcock & Krueger, 2007). Specifically, one locus that has been identified in psoriasis is the class 1 region of the major histocompatibility locus antigen cluster (MHC). There have been nine loci identified on different chromosomes that are associated with this disease, and they are named psoriasis susceptibility 1 through 9 (PSOR1 through PSOR9). These genes are located on pathways that lead to inflammation, and mutations of these genes lead to psoriasis (Nestle, Kaplan, & Barker, 2009). The most significant gene locus is PSORS-1, which is located on chromosome 6p2 in the MHC, though the specific gene has not yet been identified. This gene locus contains genes such as the HLA-C variant HLA-Cw6. This locus accounts for 35%-50% of the heritability of this disease (Smith & Barker, 2006). Interestingly, these loci are shared by other autoimmune and inflammatory diseases such as inflammatory bowel disease, type1 diabetes, multiple sclerosis, and atopic dermatitis, which indicates that these complex inflammatory diseases have a similar root cause (Lowes, Bowcock & Krueger, 2007). The MHC has a low penetrance of only about 10%; this suggests that other factors should also be considered in the etiology of this disease (Lowes, Bowcock & Krueger, 2007). Another set of genes that have the ability to affect the immune system are those that are involved with keratinocyte differentiation. Specifically, variants in the SLC9A3R1/NAT9 region and loss of the RUNX binding site are factors that could affect regulation of the immune synapse (Lowes, Bowcock & Krueger, 2007). Another gene pool to be considered is alleles that encode IL-12, IL-19/20, and IRF2, as these also play a role in the pathophysiology of psoriasis (Lowes, Bowcock & Krueger, 2007).

 Figure: The genetic linkage of plaque psoriasis 

Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580

There are also environmental factors at play which contribute to this disease. These include prolonged psychological stress and trauma and infections in the body (Smith & Barker, 2006). Another environmental trigger is changes in the climate (Smith & Barker, 2006). Certain medications and drugs may also induce psoriasis. Specifically, drug-induced psoriasis may occur with the use of medications such as beta blockers, lithium, non-steroidal anti-inflammatory drugs (Jain, 2012) and TNF inhibitors (Guerra & Gisbert, 2013).

</style>

<br>

<style justify>

In people who have this condition, skin cells proliferate much faster than normal (Raychaudhuri, Maverakis & Raychaudhuri, 2014). Specifically, skin cells are replaced 3-5 days in those who have the condition, as opposed to the regular cycle of 28-30 days (Parrish, 2012). In those that have psoriasis, their immunological functioning is an amplification of the immune activity that takes place in regular skin cells.

The dendritic cell is an antigen-presenting cell, and it is activated by the presence of a foreign substance in the cell. The nature of this autoimmune diseases causes the body to recognize its own cells as foreign. Upon detecting an antigen, the dendritic cell travels to the lymph node and presents the antigen to the naive T-cell using co-stimulatory signals. Dendritic cells function to bridge the innate immune system and adaptive immune system, and are increased in psoriatic lesions (Ouyang, 2010). Activated dendritic cells contribute cytokines including IFN-, IL-20, IL-12 and IL-23, which in turn activates the naïve T-cell (Lowes, Bowcock & Krueger, 2007). The T-cells migrate from the dermis to the epidermis. Following extravasation into the skin, T-cell-derived proinflammatory cytokines are synthesized and secreted; such as tumor necrosis factor-α, interleukin-1β, interleukin-6, interleukin-36 and interleukin-22 (Nestle, Kaplan, & Barker, 2009). When these cytokines bind to their receptors, intracellular protein cascades are activated, which ultimately leads to keratinocyte hyperproliferation and the formation of psoriatic plaque (Nestle, Kaplan, & Barker, 2009). Specifically, IL-36γ is believed to be the biomarker that is unique in the development of psoriasis as opposed to other inflammatory skin diseases. Phosphorylation of specific cell surface biomarker activates another family of signalling proteins: STAT proteins. The STAT proteins, once activated, dimerize and translocate to the cell nucleus where they regulate the genes that are responsible for the differentiation and migration of immune cells that are involved in psoriasis. There occurs a downstream activation of numerous IFN-responsive genes through signal transducer and activator of transcription 1 (STAT1) (Lew, Bowcock & Krueger, 2004). The key cytokines that can activate STAT or NF-B transcription factors (which are involved in amplifying inflammation) include TNFs, lymphotoxin (LT), IL-1, IL-17, IL-20, IL-22 and IFNs. Interleukin-22 works to induce keratinocytes to secrete neutrophil-attracting cytokines (Lew, Bowcock & Krueger, 2004). In response to these chemical messages from T-cells, keratinocytes also secrete proinflammatory cytokines, such as IL-1, IL-6, and TNF-α. These cytokines signal the activation of downstream inflammatory cells, which arrive to the site and stimulate additional inflammation (Nestle, Kaplan, & Barker, 2009). The hyper activation of the keratinocytes is maintained through molecules such as TGF-, IL-1, IL-6 and IL-20, which may act as keratinocyte autocrine and paracrine growth factors (Lew, Bowcock & Krueger, 2004). This creates an ongoing process of cell activation and immune responses, ultimately resulting in an accumulation of epidermal and immune cells, which leads to a thickened and inflamed epidermis.

 Figure: Cytokine networks in psoriasis 

Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html </style>

<br>

<style justify>TEXT</style>

<br>

<style justify>TEXT</style>

<br>

Dogra, S., & Mahajan, R. (2016). Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal, 7(6), 471.

Gudjonsson, J. E., Johnston, A., Sigmundsdottir, H., & Valdimarsson, H. (2004). Immunopathogenic mechanisms in psoriasis. Clinical & Experimental Immunology, 135(1), 1-8.

Guerra, I., & Gisbert, J. P. (2013). Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents. Expert review of gastroenterology & hepatology, 7(1), 41-48.

Jain, S. (2012). Dermatology: illustrated study guide and comprehensive board review. Springer Science & Business Media.

Langley, R. G., Krueger, G. G., & Griffiths, C. E. M. (2005). Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases, 64(suppl 2), ii18-ii23.

Lew, W., Bowcock, A. M., & Krueger, J. G. (2004). Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘Type 1’inflammatory gene expression. Trends in immunology, 25(6), 295-305.

Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007). Pathogenesis and therapy of psoriasis. Nature, 445(7130), 866-873.

Mak, R. K. H., Hundhausen, C., & Nestle, F. O. (2009). Progress in understanding the immunopathogenesis of psoriasis. Actas dermo-sifiliograficas, 100, 2-13.

Nestle, F., Kaplan, D., & Barker, J. (2009). Psoriasis. New England Journal Of Medicine, 361(5), 496-509. http://dx.doi.org/10.1056/nejmra0804595

Ouyang, W. (2010). Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine & growth factor reviews, 21(6), 435-441.

Palfreeman, A. C., McNamee, K. E., & McCann, F. E. (2013). New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther, 7, 201-210.

Parisi, R., Symmons, D. P., Griffiths, C. E., & Ashcroft, D. M. (2013). Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377-385.

Parrish, L. (2012). Psoriasis: symptoms, treatments and its impact on quality of life. British journal of community nursing, 17(11), 524-528.

“Plaque Psoriasis Pictures”. Healthline. Retrieved 2017-03-29.

“Psoriasis Symptoms and Triggers”. WebMD. Retrieved 2017-03-29.

Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014). Diagnosis and classification of psoriasis. Autoimmunity reviews, 13(4), 490-495.

Raut, A. S., Prabhu, R. H., & Patravale, V. B. (2013). Psoriasis clinical implications and treatment: a review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 30(3).

Smith, C. H., & Barker, J. N. W. N. (2006). Psoriasis and its management. BMJ: British Medical Journal, 333(7564), 380.

<br>